BioNovoGene
Latest round
- Series A
Last raised
- Jun 2023
Total raised
- $29M
Investors
- 5
About BioNovoGene
Established in 2013 and based in Suzhou, China, BioNovoGene is a biopharmaceutical company that provides metabolomics technology services, clinical products and big data services. By 2023, the company has provided metabolomics services to more than 400 research institutes, 400 tertiary hospitals and food and pharmaceutical companies in China and abroad. At the same time, the company has obtained the qualifications of CMA certified enterprise and high-tech enterprise, more than 30 intellectual property rights, and more than 20 clinically registered products. The company's business segments include histology technology services, clinical mass spectrometry, histology clinical products and biological big data platform, covering metabolomics, proteomics testing services, clinical R&D and testing., covering more than 100 niche assays and analysis services. The company also has a cloud data analysis system, BioDeep, which provides a massive metabolite library and core matching algorithm support.
Who invested in BioNovoGene
5 investors across 4 rounds
See all investors in BioNovoGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BioNovoGene
Who invested in BioNovoGene?
BioNovoGene has 5 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BioNovoGene raised?
BioNovoGene has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did BioNovoGene last raise money?
BioNovoGene's most recent round on record is a Series A, in Jun 2023.
What does BioNovoGene do?
Established in 2013 and based in Suzhou, China, BioNovoGene is a biopharmaceutical company that provides metabolomics technology services, clinical products and big data services.
Where is BioNovoGene headquartered?
BioNovoGene is headquartered in Suzhou, China.
Which VCs invest in companies like BioNovoGene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at BioNovoGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like BioNovoGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.